COVID-19 convalescent plasma: all 29 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• VA CoronavirUs Research and Efficacy Studies-1TerminatedNCT04539275Phase 3Results posted
• ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)TerminatedNCT04432272Phase 2Results posted
• Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized PatientsCompletedNCT04421404Phase 2Results posted
• COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.CompletedNCT04397757Phase 1Results posted
• Efficacy and Safety of COVID-19 Convalescent PlasmaCompletedNCT04397523Not applicableResults posted
• Convalescent Plasma for Early Treatment of COVID-19TerminatedNCT04390503Phase 2Results posted
• COVID-19 Convalescent Plasma for Mechanically Ventilated PopulationCompletedNCT04388527Phase 1Results posted
• Convalescent Plasma to Limit SARS-CoV-2 Associated ComplicationsCompletedNCT04373460Phase 2Results posted
• Plasma Therapy of COVID-19 in Severely Ill PatientsCompletedNCT04359810Phase 2Results posted
• Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized PatientsCompletedNCT04354831Phase 2Results posted
• COVID-19 Convalescent PlasmaCompletedNCT04340050Early Phase 1Results posted
• Convalescent Plasma to Stem Coronavirus (CSSC-001)CompletedNCT04323800Phase 2Results posted
• Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19CompletedNCT05595538Early Phase 1
• Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19Status unknownNCT04836260Phase 3
• Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)Status unknownNCT04712344Phase 2
• Convalescent Plasma for Treatment of COVID-19CompletedNCT04649879Phase 2/3
• Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19TerminatedNCT04567173Phase 2/3
• Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)CompletedNCT04554992Phase 1
• Convalescent Plasma as Potential Therapy for Severe COVID-19 PneumoniaCompletedNCT04535063Phase 3
• Convalescent Plasma for COVID-19 PatientsCompletedNCT04516954Early Phase 1
• Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19WithdrawnNCT04467151Phase 2
• Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.Status unknownNCT04395170Phase 2/3
• Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)CompletedNCT04390178Phase 1/2
• Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying StudyCompletedNCT04384497Phase 1/2
• Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 InfectionCompletedNCT04375098Phase 2
• Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.CompletedNCT04374526Phase 2/3
• CoVID-19 Plasma in Treatment of COVID-19 PatientsCompletedNCT04355897Early Phase 1
• Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory FailureTerminatedNCT04353206Early Phase 1
• Anti COVID-19 Convalescent Plasma TherapyStatus unknownNCT04345679Early Phase 1

← COVID-19 convalescent plasma overview